CLEC1B and coronary artery disorder: Given that podoplanin has also been shown to be expressed in advanced atherosclerotic lesions, and increased levels of soluble CLEC-2 may be associated with increased risk for CAD and may predict death and vascular events in patients with stroke, inhibition of CLEC-2 and podoplanin may be a novel therapy for cardiovascular disease that has yet to be investigated in clinical trials (163, 164, 165).